ProShares Ultra NASDAQ Biotechnology
41 hedge funds and large institutions have $24.1M invested in ProShares Ultra NASDAQ Biotechnology in 2018 Q1 according to their latest regulatory filings, with 5 funds opening new positions, 12 increasing their positions, 8 reducing their positions, and 4 closing their positions.
50% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 8
25% more first-time investments, than exits
New positions opened: 5 | Existing positions closed: 4
3% more funds holding
Funds holding: 40 → 41 (+1)
0.03% more ownership
Funds ownership: 6.6% → 6.63% (+0.03%)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
17% less capital invested
Capital invested by funds: $29M → $24.1M (-$4.96M)
26% less call options, than puts
Call options by funds: $15.9M | Put options by funds: $21.6M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
OPPM
Opus Point Partners Management
New York
|
+$3.42M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$1.21M |
| 3 |
BRC
Bell Rock Capital
Rehoboth Beach,
Delaware
|
+$401K |
| 4 |
Simplex Trading
Chicago,
Illinois
|
+$320K |
| 5 |
CIA
Capital Investment Advisors
Atlanta,
Georgia
|
+$231K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.87M |
| 2 |
VF
Virtu Financial
New York
|
-$2.67M |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$2.61M |
| 4 |
PCA
Private Capital Advisors
Darien,
Connecticut
|
-$1.76M |
| 5 |
CT
CMT Trading
Chicago,
Illinois
|
-$280K |
BIB Hedge Fund Activity: Q1 2018 in Review
41 of the 4,363 institutional investors tracked by Wall St. Rank reported a position in ProShares Ultra NASDAQ Biotechnology (BIB) for Q1 2018, worth a combined $24.1M — down 17% from $29M a quarter earlier.
Buyers outnumbered sellers: 5 funds opened new BIB positions and 4 closed out — a net gain of 1 holder — while 12 added to existing stakes and 8 trimmed.
The largest buyer was Opus Point Partners Management, adding an estimated $3.42M. The largest seller was Tower Research Capital (TRC), cutting an estimated $2.87M.
- 41 institutional investors held ProShares Ultra NASDAQ Biotechnology (BIB) as of Q1 2018, up from 40 in Q4 2017.
- Funds reported $24.1M of ProShares Ultra NASDAQ Biotechnology stock for Q1 2018, down 17% quarter-over-quarter.
- 5 funds opened new ProShares Ultra NASDAQ Biotechnology positions in Q1 2018 and 4 closed out, a net change of +1 holder.
- The largest ProShares Ultra NASDAQ Biotechnology buyer in Q1 2018 was Opus Point Partners Management, an estimated $3.42M added.
- The largest ProShares Ultra NASDAQ Biotechnology seller in Q1 2018 was Tower Research Capital (TRC), an estimated $2.87M sold.
Based on aggregated 13F filings for Q1 2018.